Business context and reporting period
Entity and period mismatch: The request identifies Paranovus Entertainment Technology Ltd. and “2017 Q4,” but the supplied filing is for Happiness Biotech Group Limited, a China-focused nutraceutical and dietary-supplement company. It is a Form 20-F annual report covering the fiscal year ended March 31, 2019, with FY2018 comparatives; it does not provide standalone Q4 results.
The filing says it was submitted to provide certified FY2019 financial statements omitted from the company’s Form F-1 registration statement. The statements are prepared under U.S. GAAP and were audited by Briggs & Veselka Co., which issued an unqualified opinion. The auditor did not express an opinion on internal control over financial reporting.
Financial performance and position
| Metric | FY ended Mar. 31, 2019 | FY ended Mar. 31, 2018 |
|---|---|---|
| Revenue | $63.94 million | $61.50 million |
| Gross profit / margin | $32.25 million / 50.4% | $29.35 million / 47.7% |
| Operating income / margin | $21.84 million / 34.2% | $20.24 million / 32.9% |
| Net income / margin | $18.72 million / 29.3% | $17.49 million / 28.4% |
| Basic and diluted EPS | $0.81 | $0.76 |
| Net cash from operating activities | $6.54 million | $12.93 million |
| Cash and cash equivalents, at year-end | $14.80 million | $8.88 million |
| Total assets | $65.68 million | $53.40 million |
| Total liabilities / short-term bank borrowings | $4.76 million / $1.04 million | $8.84 million / $1.49 million |
| Shareholders’ equity | $60.92 million | $44.55 million |
Revenue increased about 4.0%, gross profit 9.9%, operating income 7.9%, and net income 7.0% year over year. Gross, operating, and net margins each improved. Operating cash flow declined about 49.4% despite higher earnings. Cash increased by $5.92 million, and year-end cash exceeded short-term borrowings by approximately $13.76 million. Current assets were $54.84 million against $4.76 million of current liabilities; accounts receivable were $32.01 million.
Material changes and notable items
- Advertising costs rose to $3.22 million from $2.05 million, while shipping and handling costs fell to $1.84 million from $2.30 million. Total operating expenses increased to $10.40 million from $9.11 million.
- Operating cash flow was affected by a $6.03 million increase in prepaid expenses and $2.26 million in other assets, partly offset by earnings and other working-capital movements. The company reported a $5.94 million raw-material deposit and $2.26 million of advertising and celebrity-endorsement prepayments.
- Foreign-currency translation shifted from a $3.17 million gain in FY2018 to a $2.99 million loss in FY2019; comprehensive income consequently declined to $15.74 million from $20.66 million.
- The company completed a common-control reorganization in August 2018 and retrospectively presented the group as if the reorganization had taken effect at the start of the periods shown. In March 2019, it subdivided shares, cancelled shares, and sold additional shares at par; 23 million ordinary shares were outstanding at year-end.
- The company paid no dividends in either period. PRC law and statutory reserves restrict the ability to transfer certain subsidiary funds or distribute them as dividends.
Outlook, risks and contingencies
- No financial guidance or quantified outlook is provided. Management said adoption of ASC 606 on April 1, 2019 was not expected to have a significant financial effect, but would require expanded revenue disclosures.
- The main operating entity’s preferential 15% PRC income-tax status was being reapplied for. If approval was not obtained, the filing says a 25% rate would apply for calendar 2019; the preferential rate was approved for 2019–2021 only if the application succeeded.
- Substantially all operations and cash are in China and denominated in RMB. The filing highlights exchange-rate, currency-convertibility, PRC political/regulatory, credit, and variable interest-rate risks. PRC bank deposits are not insured by the FDIC or similar programs.
- Accounts receivable had no recorded allowance for doubtful accounts; customers generally received credit terms of up to 180 days. The balance was $32.01 million at year-end, and management considered it fully recoverable.
- Two suppliers represented 12.7% and 11.7% of FY2019 raw-material purchases. The company said alternative suppliers were available. Buildings and land-use rights were pledged as collateral for bank loans, and certain loans also had personal guarantees.
- The filing reported no material purchase commitments, significant leases, unused letters of credit, or pending legal proceedings at March 31, 2019. Subsequent events included renewal of a $1.04 million bank loan and a new $581,844 one-year loan at 5.66% in June 2019.
- The filing’s cover checks “No” for having filed all reports required during the preceding 12 months. This apparent reporting-status issue merits review alongside the filing’s special-report explanation.
Investor verification priorities
- Confirm the issuer and period: the supplied document concerns Happiness Biotech Group Limited and FY2019, not the named company or 2017 Q4.
- Review the collectability and aging of the $32.01 million receivables balance and the conversion of FY2019 earnings into operating cash.
- Verify fulfillment, refund terms, and counterparty protections for the $5.94 million supplier deposit and the marketing and endorsement prepayments.
- Confirm the outcome and continuing eligibility of the preferential PRC tax status, and assess the potential effect of a higher tax rate.
- Assess access to PRC-held cash, currency-conversion restrictions, foreign-exchange exposure, and restrictions on subsidiary distributions.
- Clarify the cover-page “No” response regarding required filings and review the pledged collateral, guarantees, and post-year-end borrowing terms.